ArticleCureus2026
Exploratory Analysis of MicroRNA (miRNA) as a Prognostic and Predictive Biomarker in Locally Advanced and Metastatic Gastric Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose Emerging evidence suggests that microRNAs (miRNAs) can function as oncogenes or tumor suppressors, playing an important role in pathogenesis, treatment response, and survival outcomes. This study aims to identify miRNAs as prognostic and predictive biomarkers in locally advanced and metastatic gastric cancer. Materials and methods This study was a prospective exploratory study of patients with gastric cancer from April 2018 to October 2022. Tissues of 50 paired locally advanced and metastatic gastric cancer patients were examined for the expression level of oncomiRs miR-21, miR-200b, miR-27a, miR-93, miR-18a, miR-25, miR-210, and miR-29c and tumor suppressor miR-204 using quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR), and the relevant association with clinical factors was analyzed. Results The expression of miR-29c, miR-27a, and miR-25 was differentially regulated into low and high based on the twofold change. Patients with low miR-29c expression demonstrated an increased propensity for metastasis (P = 0.03). Downregulation of miR-25 was significantly associated with the absence of peritoneal involvement (P < 0.0001) and liver metastasis (P < 0.005). High expression of miR-27a was associated with a better response to chemotherapy (P = 0.04). It was observed that the median follow-up duration was 7.98 months (range, 0.60-46.93 months). Notably, patients in the low miR-27a expression group had significantly better overall survival compared to the high expression group (12.03 (5.69-18.37) months vs 4.90 (3.47-6.33) months; P = 0.02). Conclusion The differentially regulated miRNAs, namely, miR-29c, miR-27a, and miR-25, may be used as predictive and prognostic biomarkers in advanced gastric cancer which require further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.